Issue 75, 2022

A pH-responsive crosslinker platform for antibody-drug conjugate (ADC) targeting delivery

Abstract

We report a new 1–6 self-immolative, traceless crosslinker derived from the natural product gallic acid. The linker acts through a pH-dependent mechanism for drug release. This 5-(hydroxymethyl)pyrogallol orthoester derivative (HMPO) was stable for 24 hours at pH values of 7.4 and 6.6 and in plasma, releasing molecules bound to the hydroxymethyl moiety under acid-dependent stimuli at pH 5.5. The linker was non-toxic and was used for the conjugation of Doxorubicin (Doxo) or Combretastatin A4 with Cetuximab. The ADCs formed showed their pH responsivity reducing cell viability of A431 and A549 cancer cells better than Cetuximab alone.

Graphical abstract: A pH-responsive crosslinker platform for antibody-drug conjugate (ADC) targeting delivery

Supplementary files

Article information

Article type
Communication
Submitted
30 May 2022
Accepted
21 Jun 2022
First published
31 Aug 2022
This article is Open Access
Creative Commons BY license

Chem. Commun., 2022,58, 10532-10535

A pH-responsive crosslinker platform for antibody-drug conjugate (ADC) targeting delivery

F. Migliorini, E. Cini, E. Dreassi, F. Finetti, G. Ievoli, G. Macrì, E. Petricci, E. Rango, L. Trabalzini and M. Taddei, Chem. Commun., 2022, 58, 10532 DOI: 10.1039/D2CC03052G

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements